
Please try another search
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
Name | Age | Since | Title |
---|---|---|---|
Christophe Douat | 58 | 2014 | Chief Executive Officer & Director |
Philippe Guy | - | 2010 | Chairman of the Board |
Virginie Lleu | - | 2016 | Director |
Tone Kvale | 55 | 2022 | Director |
Elisabeth Kogan | - | 2020 | Independent Vice Chairman |
Rachel Almeras | - | - | Censor |
Olivier-Sabri Markabi | 66 | 2017 | Board Observer |
Pascal Touchon | 61 | 2025 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review